Sacubitril: Discovery, Development, Safety and Pharmacovigilance
Sacubitril is an orally administered prodrug whose active metabolite, LBQ657, inhibits neprilysin, a peptidase involved in degrading several biologically active peptides. It was developed as a component of a combined angiotensin-receptor–neprilysin inhibition strategy for heart failure. The authorised clinical medicine contains both sacubitril and valsartan. Its efficacy, major clinical outcomes and most adverse-event evidence derive from the combination, not an authorised sacubitril monotherapy. [1–3]
That distinction is fundamental. Although sacubitril is the subject of this INN-centred lifecycle article, the clinical intervention tested in the landmark trials was a pharmacologically coordinated regimen that changes natriuretic-peptide breakdown while blocking angiotensin II type 1 receptors. The scientific rationale, regulatory identity and interpretation of safety therefore depend on both molecules. Valsartan merits its own INN article, but combination outcomes and commercial sales cannot be assigned in full to either constituent.
- Sacubitril: Discovery, Development, Safety and Pharmacovigilance
Physiological foundations and discovery
Why neprilysin became a target
The natriuretic-peptide system opposes several effects of maladaptive neurohormonal activation in heart failure. Natriuretic peptides promote natriuresis, vasodilatation and other potentially protective responses; neprilysin metabolises these and additional peptide substrates. Inhibiting neprilysin can enhance endogenous peptide activity, but neprilysin inhibition alone is not sufficient to counter all components of renin–angiotensin system activation. [1,4]
Earlier dual inhibition of neprilysin and angiotensin-converting enzyme, including the investigational medicine omapatrilat, highlighted a serious limitation: angioedema arising in part from altered degradation pathways for vasoactive peptides such as bradykinin. This created a reason to combine neprilysin inhibition with an angiotensin receptor blocker rather than with ACE inhibition. The resulting strategy still carries angioedema risk and requires separation from ACE inhibitors by the period specified in the product information. The switch from a mechanistically appealing idea to a safer combination design is a central development lesson, not proof that angioedema has been eliminated. [1,4]
From the prodrug to the fixed combination
Novartis developed the LCZ696 programme, pairing sacubitril (originally designated AHU377) with the established angiotensin II receptor antagonist valsartan. After absorption, sacubitril is converted to LBQ657. Valsartan blocks AT1 receptors, preventing angiotensin II-mediated vasoconstriction, aldosterone effects and related responses, while LBQ657 inhibits neprilysin. The two actions are complementary but pharmacologically different. [1]
The product's development, licensing and commercial history should be understood at the level of the fixed combination and Novartis programme. Neither a claim of standalone sacubitril marketing nor attribution of all combination revenue to the individual INN would be justified. Published trials and regulatory summaries generally describe the medicine as sacubitril/valsartan or angiotensin-receptor–neprilysin inhibitor (ARNI).
Regulatory identity and authorised use
The European Medicines Agency records Entresto as containing sacubitril and valsartan, with first EU marketing authorisation on 19 November 2015. The current EMA EPAR provides the legally relevant product-information annexes, with a product-information update dated 13 January 2026. The SmPC should be consulted for the current authorised adult and paediatric heart-failure populations, dosage forms, titration, exclusions and monitoring requirements. [1]
The US and EU labels may differ in indication wording and age restrictions. A publication describing a US label change does not itself amend the EU authorisation. For case processing, the formulation, manufacturer, strength, clinical indication and authorisation territory therefore form part of the product's regulatory identity.
A distinction in nomenclature is also needed: some fixed-dose tablet strengths are expressed using the amounts of sacubitril and valsartan, while clinical trials often report the combined dose. Comparing a trial's “200 mg twice daily” with a label's “97 mg/103 mg twice daily” requires attention to the components of the actual formulation rather than assuming that the figures represent incompatible regimens. [1–3]
Clinical Development and Trial Interpretation
PARADIGM-HF: the pivotal HFrEF trial
PARADIGM-HF randomised 8,442 patients with symptomatic heart failure and reduced ejection fraction after a run-in period testing tolerability of both study treatments. Sacubitril/valsartan was compared with enalapril. Over a median follow-up of approximately 27 months, the primary composite of cardiovascular death or first hospitalisation for heart failure occurred in 21.8% versus 26.5% (hazard ratio 0.80; 95% CI 0.73–0.87). All-cause mortality was 17.0% versus 19.8% (hazard ratio 0.84). The trial was stopped early under prespecified rules. [2]
The observed benefit is attributable to the combination regimen in the studied population. It cannot be assigned to sacubitril monotherapy. The active-treatment run-in also matters: tolerability and efficacy in randomised patients should not be assumed for clinically unstable people who could not tolerate the trial's preliminary treatment.
PARAGON-HF: a different clinical population
PARAGON-HF evaluated 4,822 patients with heart failure and ejection fraction at least 45%, comparing sacubitril/valsartan against valsartan. Its primary outcome combined total heart-failure hospitalisations and cardiovascular death. The rate ratio was 0.87 (95% CI 0.75–1.01; P=0.06), so the primary analysis did not meet the conventional significance threshold. The result requires its own interpretation rather than being declared equivalent to PARADIGM-HF. [3]
| Trial | Population | Comparator | Interpretation |
|---|---|---|---|
| PARADIGM-HF | Symptomatic reduced-EF heart failure | Enalapril | Lower cardiovascular-death/first-HF-admission composite with combination treatment |
| PARAGON-HF | Symptomatic heart failure, EF at least 45% | Valsartan | Primary recurrent-event composite did not meet statistical significance |
These trials differed in populations, comparator therapy and endpoint construction. PARAGON-HF also included repeated admissions, unlike the first-event primary outcome of PARADIGM-HF. Subgroup findings and subsequent studies can inform further assessment, but do not rewrite a prespecified primary result.
Beyond the pivotal trials
Post-authorisation studies investigated additional initiation settings and other outcomes. Trial evidence, observational treatment experience and contemporary clinical recommendations each serve different purposes. Biomarker changes are not automatically equivalent to reduced mortality, and results in adults do not define the authorised paediatric population. Current EU product information should be used for the latter. [1]
Relationship Between Drug Formulation and Clinical Practice
Combination-tablet strengths identify their individual components, whereas published trial descriptions may quote an aggregated tablet dose. For example, a tablet containing sacubitril 97 mg and valsartan 103 mg may be described as a 200 mg combination dose in clinical-trial reporting. Comparisons of exposure must preserve that distinction.
Treatment initiation and up-titration depend on haemodynamic stability, blood pressure, renal function, potassium and interacting medicines. A trial target is not a universal starting dose. Product-specific contraindications and dose-adjustment rules govern clinical implementation. [1]
Safety Profile and Risk Relationships
Hypotension and renal effects
Symptomatic hypotension may occur with sacubitril/valsartan, particularly during treatment initiation or dose escalation, and in patients with volume depletion or other blood-pressure-lowering therapies. Suspected reports should document baseline and serial blood pressure, symptoms, dose changes, concurrent diuretics, illness and outcome. Treatment-associated changes in kidney function require assessment of underlying heart failure, renal vascular disease, hydration and interacting medicines, rather than automatic assignment to one ingredient. [1]
The valsartan component blocks angiotensin II AT1 receptors; hyperkalaemia and altered renal haemodynamics may therefore be clinically significant. Potassium-sparing treatments, supplementation, reduced kidney function and intercurrent illness can compound risk. Product information sets the appropriate precautions; these are requirements for the combination, not proof that neprilysin inhibition independently causes all potassium abnormalities.
Angioedema and medicine switching
Angioedema is an important serious risk. Unlike an ACE inhibitor, valsartan does not inhibit ACE, but neprilysin inhibition still changes the metabolism of biologically active peptides. Combining sacubitril/valsartan with an ACE inhibitor is contraindicated, and the EU SmPC specifies a 36-hour separation when switching between the two regimens. Certain previous angioedema histories are contraindications. [1]
Suspected angioedema must be characterised medically: site of swelling, tongue or airway involvement, respiratory compromise, treatment and recovery, previous episodes, recent ACE inhibitor exposure and the actual switch interval. The absence of airway intervention does not automatically exclude the diagnosis; conversely, nonspecific peripheral oedema cannot be coded as confirmed airway angioedema without evidence.
Pregnancy and hepatic impairment
Risks arising from renin–angiotensin system blockade make pregnancy exposure consequential. The EU product information contraindicates sacubitril/valsartan in the second and third trimesters, with additional precautions for earlier pregnancy. Reproductive-safety evaluations need the time of exposure, maternal indication, other therapies and fetal or neonatal findings. Severe hepatic impairment is also a contraindication in the EU SmPC. [1]
Special-population assessment must reflect current, local product information. Statements applicable to an adult trial population do not establish safe dosing in children or in advanced organ impairment.
EU Pharmacovigilance Implementation
Applicable European medicines legislation governs marketing authorisation holders' pharmacovigilance responsibilities. GVP provides scientific and procedural guidance for case management, signal evaluation, quality systems and ongoing benefit–risk assessment. The safety profile of sacubitril/valsartan should be evaluated against the authorised combined product, even when a spontaneous reporter names only sacubitril. [4]
Case Data and Medical Follow-up
| Question | Useful evidence | Why it matters |
|---|---|---|
| Was the correct product identified? | Full ingredient combination, strength, brand, dates | Prevents incomplete exposure attribution |
| Was an ACE inhibitor also used? | Name, last administration and ARNI first administration | Characterises prohibited overlap or insufficient switching interval |
| Is angioedema clinically established? | Anatomical site, airway signs, treatment, recovery | Separates severe reactions from vague swelling |
| Are renal or electrolyte events substantiated? | Serial creatinine and potassium, baseline disease, other medicines | Supports medical assessment and alternate explanations |
| Did hypotension follow dose change? | Blood pressure, titration, diuretics and fluid status | Connects chronology and contributory factors |
Signals involving angioedema, hypotension, renal changes, hyperkalaemia, pregnancy exposure or use errors require medically informed evaluation and accurate product coding. Case-series findings should be considered with clinical trials, spontaneous-report limitations and appropriate exposure estimates. A temporal relationship supports investigation but does not itself prove causality.
Governance and an Illustrative Inspection Scenario
Consider a hypothetical series of reported facial-swelling events after switching from an ACE inhibitor. An inspector assessing the pharmacovigilance system could ask whether the marketing authorisation holder recovered exact administration dates, evaluated possible 36-hour interval errors, medically reviewed the reported diagnoses, and connected the cumulative findings to signal decisions and risk-minimisation oversight. This is an illustrative inspection scenario, not an actual cited finding.
Documentation should connect the original source information, case validity, medical assessment, coded terms, cumulative decision and responsible governance body. For a combination medicine, this also requires consistent product identification across intake channels and vendor systems.
Key Takeaways
Sacubitril entered clinical practice through the development of a coordinated neprilysin-inhibition and angiotensin-receptor-blockade strategy. Its pivotal clinical benefits and risks belong to sacubitril/valsartan as a regimen, not an independently authorised sacubitril monotherapy. Interpretation of PARADIGM-HF and PARAGON-HF demands attention to populations, comparators and primary endpoints. The most important ongoing safety questions concern haemodynamic effects, potassium and renal function, angioedema, interactions including ACE inhibitors, and pregnancy.
References
- European Medicines Agency. Entresto: EPAR and authorised EU product information, updated 13 January 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/entresto
- McMurray JJV, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
- Solomon SD, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655
- European Medicines Agency. Good pharmacovigilance practices. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
Regulatory Note
This article describes the INN sacubitril in the context of the EU-authorised sacubitril/valsartan combination. Current authorised regional product information governs indications, contraindications, dosing and safety precautions. Clinical trials and illustrative PV workflows must not be presented as independent regulatory requirements.